The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Choi, Sun Y ^a   Park, HeonSoo ^b   Kang, Myung K ^b   Lee, Dong K ^b   Lee, Kang D ^c   Lee, Hyoung S ^c   Kim, Sung W ^c   Lee, Eun N ^a   Hong, Jong C ^b  

^a Dong A University College of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Kosin University College of Medicine   (South Korea)

Author keywords

BRAF mutation; Papillary thyroid microcarcinoma; Prognosis

Indexed keywords

B RAF KINASE;

ADULT; AGE; ARTICLE; BRAF V600E; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENDER; GENE MUTATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; NECK DISSECTION; PAPILLARY THYROID MICROCARCINOMA; PREVALENCE; RETROSPECTIVE STUDY; THYROID CARCINOMA; THYROIDECTOMY; WILD TYPE;

CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 84887372198     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-291     Document Type: Article

References (14)

1. Ahn HY, Park YJ. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med 2009, 77:537-542.
2. Rassael H, Thompson LD, Heffess CS. A rationale for conservative management of microscopic papillary carcinoma of the thyroid gland: a clinicopathologic correlation of 90 cases. Eur Arch Otorhinolaryngol 1998, 255:462-467. 10.1007/s004050050100, 9833215.
3. Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 2012, 122:1634-1640. 10.1002/lary.23371, 22549559.
4. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012, 36:310-317. 10.1007/s00268-011-1383-1, 22190222.
5. Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 2012, 39:198-203. 10.1016/j.anl.2011.07.011, 21862261.
6. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246:466-470. 10.1097/SLA.0b013e318148563d, 1959359, 17717450.
7. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK. The BRAFmutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol 2005, 63:588-593.
8. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007, 17:1085-1092. 10.1089/thy.2007.0005, 18047430.
9. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, ONeill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013, 309:1493-1501. 10.1001/jama.2013.3190, 3791140, 23571588.
10. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15:191-205. 10.1677/ERC-07-0212, 18310287.
11. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009, 94:1612-1617. 10.1210/jc.2008-2390, 19190105.
12. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009, 16:240-245. 10.1245/s10434-008-0233-3, 19034577.
13. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003, 63:4561-4567.
14. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid 2013, 23(11):1423-1430. 10.1089/thy.2013.0036, 23496275.